Dcf Advisers, LLC Fibrogen Inc Transaction History

Dcf Advisers, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$18.57 - $35.68 $318,011 - $611,020	-17,125 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$31.0 - $55.72 $430,125 - $773,115	-13,875 Reduced 44.76%	17,125 $594,000
Q4 2020 Feb 12, 2021	BUY	$37.09 - $48.97 $259,630 - $342,790	7,000 Added 29.17%	31,000 $1.15 Million
Q3 2020 Nov 13, 2020	BUY	$40.47 - $45.5 $586,815 - $659,750	14,500 Added 152.63%	24,000 $987,000
Q2 2020 Aug 13, 2020	SELL	$32.57 - $42.83 $130,280 - $171,320	-4,000 Reduced 29.63%	9,500 $385,000
Q1 2020 May 12, 2020	SELL	$23.3 - $45.96 $93,200 - $183,840	-4,000 Reduced 22.86%	13,500 $469,000
Q4 2019 Feb 12, 2020	BUY	$34.58 - $48.06 $605,150 - $841,050	17,500 New	17,500 $751,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.